Canaccord Genuity Initiates Coverage On Pharming with Buy Rating, Announces Price Target of $37
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
Canaccord Genuity analyst Whitney Ijem initiates coverage on Pharming (NASDAQ:PHAR) with a Buy rating and announces Price Target of $37.
Canaccord Genuity analyst Whitney Ijem initiates coverage on Pharming (NASDAQ:PHAR) with a Buy rating and announces Price Target of $37.